PhRMA Urges FTC Not To Expand Patent Licensing Scrutiny

Law360, New York (November 1, 2012, 5:52 PM EDT) -- The Pharmaceutical Research and Manufacturers of America accused the Federal Trade Commission on Wednesday of exceeding its authority under federal merger law and discriminating against the industry by proposing to expand the types of exclusive pharmaceutical patent rights licenses that require antitrust approval.

The trade group, which goes by the acronym PhRMA, urged the FTC to abandon its plans to amend its premerger notification rules governing what types of exclusive patent rights transfers require antitrust approval, saying it unfairly singled out the pharmaceutical industry for heavier...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.